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ABSTRACT
Introduction: Effective treatments for
hormone-receptor-positive (HR?) breast cancer
(BC) following relapse/progression on
nonsteroidal aromatase inhibitor (NSAI)
therapy are needed. Initial Breast Cancer Trials
of OraL EveROlimus-2 (BOLERO-2) trial data
demonstrated that everolimus and exemestane
significantly prolonged progression-free
survival (PFS) versus placebo plus exemestane
alone in this patient population.
Methods: BOLERO-2 is a phase 3, double-blind,
randomized, international trial comparing
everolimus (10 mg/day) plus exemestane
(25 mg/day) versus placebo plus exemestane in
postmenopausal women with HR? advanced BC
with recurrence/progression during or after
Portions of the data have been presented previously:
Piccart-Gebhart MJ, Noguchi S, Pritchard KI, Burris HA,
Rugo HS, Gnant M, et al. Everolimus for postmenopausal
women with advanced breast cancer: Updated results of
the BOLERO-2 phase III trial [abstract]. Presented at the
48th Annual Meeting of the American Society of Clinical
Oncology; June 1–5, 2012; Chicago, IL. Abstract 559.
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NSAIs. The primary endpoint was PFS by local
investigator review, and was confirmed by
independent central radiology review. Overall
survival, response rate, and clinical benefit rate
were secondary endpoints.
Results: Final study results with median
18-month follow-up show that median PFS
remained significantly longer with everolimus
plus exemestane versus placebo plus
exemestane [investigator review: 7.8 versus
3.2 months, respectively; hazard ratio = 0.45
(95% confidence interval 0.38–0.54); log-rank
P\0.0001; central review: 11.0 versus
4.1 months, respectively; hazard ratio = 0.38
(95% confidence interval 0.31–0.48); log-rank
P\0.0001] in the overall population and in all
prospectively defined subgroups, including
patients with visceral metastases, patients with
recurrence during or within 12 months of
completion of adjuvant therapy, and
irrespective of age. The incidence and severity
of adverse events were consistent with those
reported at the interim analysis and in other
everolimus trials.
Conclusion: The addition of everolimus to
exemestane markedly prolonged PFS in
patients with HR? advanced BC with disease
recurrence/progression following prior NSAIs.
These results further support the use of
everolimus plus exemestane in this patient
population. ClinicalTrials.gov #NCT00863655.
Keywords: Advanced breast cancer;
Everolimus; Exemestane; Hormone receptor
positive; Nonsteroidal aromatase inhibitors;
Oncology; Postmenopausal; Progression-free
survival
INTRODUCTION
The majority of women with breast cancer (BC;
approximately 70% worldwide) have hormone-
receptor-positive (HR?) tumors [1]. Almost all of
these women will receive endocrine therapy as a
standard part of their treatment for early and/or
advanced-stage disease [2–4]. Currently, third-
generation nonsteroidal aromatase inhibitors
(NSAIs: anastrozole and letrozole) and
steroidal exemestane (EXE) represent the
preferred front-line therapy for
postmenopausal women with HR? advanced
BC [4]. However, progressive disease ultimately
develops in virtually all patients, either as early
failure to respond to endocrine therapy (de
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novo resistance) or as relapse/progression after
initial response (acquired resistance) [5].
A significant proportion of tumors in BC
patients retain their sensitivity to endocrine-
directed approaches even after disease
progression on prior endocrine therapy, and
may respond to another endocrine agent [6, 7].
In view of the favorable safety profile of
endocrine-directed agents, extending the
benefit of endocrine therapy at relapse/
progression is an important clinical
consideration. In particular, the low toxicity of
endocrine agents compared with chemotherapy
represents a major advantage in a population of
patients with a high incidence of comorbidities.
However, sequential lines of single-agent
endocrine therapy are associated with modest
clinical benefit [6, 7]. Accordingly, combination
endocrine therapies [8–10] and co-targeting of
downstream elements of the molecular
pathways associated with BC progression and
the development of endocrine resistance [e.g.,
histone deacetylase or mammalian target of
rapamycin (mTOR)] have been investigated [11,
12].
Preclinical and clinical evidence shows that
everolimus (EVE), a rapamycin derivative, has
direct anticancer effects, and that mTOR
inhibition can enhance the efficacy of
endocrine therapy in breast tumors [13–15].
The strategy of dual inhibition with endocrine
therapy and an mTOR inhibitor was
investigated in the Breast Cancer Trials of
OraL EveROlimus-2 (BOLERO-2) trial [16].
Data from the protocol-defined interim
analysis at 7.6-month median follow-up of this
randomized, placebo-controlled, phase 3 trial
demonstrated that EVE?EXE significantly
improved progression-free survival (PFS)
compared with placebo (PBO) ? EXE [hazard
ratio (HR) 0.43; P\0.001 based on local
investigator assessment; HR 0.36; P\0.001
based on the independent central radiology
assessment] [16]. This led to the recent
regulatory approval in the United States and
Europe of EVE in combination with EXE for the
treatment of postmenopausal women with
HR?, human epidermal growth factor receptor
2-negative (HER2-) advanced BC recurring or
progressing after prior NSAIs [9]. The final
analysis of PFS, other efficacy endpoints, and
updated safety are reported here.
METHODS
Details of patient selection criteria and the
clinical protocol of this study have been
previously reported [16].
Patients
Enrolled patients were adult postmenopausal
women with HR? metastatic/locally advanced
BC not amenable to surgery or radiotherapy and
progressing after anastrozole or letrozole
(defined as disease recurrence during or within
12 months of end of adjuvant treatment or
progression during or within 1 month of end of
treatment for advanced disease). Patients whose
tumors showed HER2 overexpression
(immunohistochemistry 3?) or gene
amplification (in situ hybridization positive) or
who had received prior therapy with EXE or
mTOR inhibitors were excluded.
Written informed consent was obtained
from all patients before enrollment. The
institutional review board at each participating
center approved the study, which was
conducted in accordance with the principles
of Good Clinical Practice, the provisions of the
Declaration of Helsinki of 1975, as revised in
2000 and 2008, and other applicable local
regulations. A steering committee supervised
872 Adv Ther (2013) 30:870–884
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study conduct. An independent data and safety
monitoring committee performed semiannual
safety reviews and reviewed the interim efficacy
results.
Study Design
BOLERO-2 was a multicenter, double-blind,
randomized, placebo-controlled, international
phase 3 study. Patients were randomly allocated
in a 2:1 ratio to receive EVE 10 mg/day or
matching PBO in a blinded manner; all patients
received open-label EXE 25 mg/day (N = 724).
Patients were stratified according to the
presence of visceral metastasis (yes vs no) and
sensitivity to previous hormonal therapy (yes vs
no), as previously described [16]. The primary
endpoint for this study was PFS as assessed by
local investigator [based on Response
Evaluation Criteria In Solid Tumors (RECIST)
1.0] and confirmed by central review. Secondary
endpoints included overall response rate
(complete response or partial response);
clinical benefit rate (CBR; defined as complete
response ? partial response ? stable disease for
at least 24 weeks); overall survival (OS); quality
of life (QOL), changes in bone marker levels,
and patient safety.
Study Assessments
Tumor assessments were based on computed
tomography (CT) scans or magnetic resonance
imaging (MRI) of the chest, abdomen, and
pelvis at baseline and every 6 weeks until
disease progression. Patients who discontinued
one or both study treatments for any reason
other than progression were followed with the
same assessment schedule until progression. A
bone scan or skeletal survey using radiography,
CT scanning, or MRI was required within
6 weeks before randomization. Abnormalities
observed on bone scans were assessed using
the same method every 6 weeks. After
discontinuation of treatment, patients who
progressed were followed every 3 months for
survival.
Hematologic parameters, biochemical
measures, and vital signs were assessed at
baseline and at each visit, and the lipid profile
was assessed every 6 weeks. Adverse events (AEs)
were monitored continuously throughout the
study and graded according to Common
Terminology Criteria for Adverse Events,
version 3.0 [17].
Statistical Analysis
The primary efficacy analysis of PFS by local
investigator assessment required 528 PFS events
to achieve 90% power to detect an HR of 0.74
(26% risk reduction) using a log-rank test and
2-look Lan-DeMets group [18] sequential design
with O’Brien–Fleming-type boundary at a one-
sided cumulative 2.5% significance level; one
interim analysis was conducted after observing
60% of events (previously reported) [16]. Based
on the magnitude and stability of the EVE
treatment effect over time, as well as lower-
than-expected event rates, final analysis after
slightly fewer events than planned (i.e., 510
events) was considered appropriate.
RESULTS
A total of 724 patients were randomized
between June 2009 and January 2011 to
receive EVE?EXE (n = 485) or PBO?EXE
(n = 239). Baseline characteristics were similar
between treatment groups (Table 1) [16]. At
baseline, 77% of patients had bone lesions
(21% had bone-only lesions), and of the
approximately 59% with visceral disease, 84%
had involvement at 2 or more sites.
Adv Ther (2013) 30:870–884 873
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Approximately 48% of patients had been
previously treated with tamoxifen (TAM), and
approximately 17% had previously received
fulvestrant (both in addition to the NSAI
required per inclusion criteria). Approximately
80% of patients received prior therapy for
metastatic disease, including chemotherapy
(26%), whereas 20% of patients received study
treatment as their first therapy for metastatic
disease.
At the cutoff date for the final PFS analysis,
December 15, 2011, 510 PFS events had accrued
based on local assessment and 320 per central
radiology review. The median duration of
follow-up at data cutoff was 17.7 months
(range 10.9–28.6 months). Eighty-one patients
(16.7%) in the EVE?EXE arm and 10 patients
(4.2%) in the PBO?EXE arm continued to
receive study treatment.
In the EVE?EXE arm, median duration of
exposure to EVE was 23.9 weeks (range
1.0–123.3 weeks) and median exposure to EXE
was 29.5 weeks (range 1.0–123.3 weeks). In the
PBO?EXE arm, median exposure to EXE was
14.07 weeks (range 1.0–101.0 weeks). The
Table 1 Patient demographic, baseline disease, and
treatment characteristics
Characteristic EVE1EXE
(n5 485), %
PBO1EXE
(n5 239), %
Median age, years
(range)
62 (34–93) 61 (28–90)
Race
White 74 78
Asian 20 19
Black 3 1
Other 3 2
ECOG performance
status 0
60 59
Visceral disease 58 59
Measurable diseasea 70 68
Metastatic site
Lung 30 33
Liver 33 30
Bone 77 77
Prior therapy
Setting of most recent treatment
Adjuvant 21 16
Advanced/
metastatic disease
79 84
LET or ANA as most
recent treatment
74 75
Tamoxifen 47 50
Fulvestrant 17 16
Chemotherapy (any
setting)
69 65
Chemotherapy for
metastatic BC
26 26
Radiotherapy 70 69
Number of prior therapiesb
1 or 2 46 47
Table 1 continued
Characteristic EVE1EXE
(n5 485), %
PBO1EXE
(n5 239), %
C3 54 53
From Baselga et al. [16]. Copyright  2012 Massachusetts
Medical Society. Reprinted with permission from
Massachusetts Medical Society. Any minor differences
between this table and the original report by Baselga et al.
[16] are a consequence of the investigator’s data correction
at the subsequent analysis
ANA anastrozole, BC breast cancer, ECOG Eastern
Cooperative Oncology Group, EVE everolimus, EXE
exemestane, LET letrozole, PBO placebo
a All other patients had C1 mainly lytic bone lesion
b Prior therapies include those used in the adjuvant setting
or to treat advanced disease
874 Adv Ther (2013) 30:870–884
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median relative dose intensities for EVE and
EXE were 86% and 100%, respectively, in the
EVE?EXE arm. The median relative dose
intensity for EXE was 100% in the PBO?EXE
arm. This represents an increase in drug
exposure of 117.5 patient-years (60%) in the
EVE?EXE arm and 23.7 patient-years (32%) in
the PBO?EXE arm compared with the protocol-
specified interim analysis [16].
The main reason for treatment
discontinuation in both study arms was
disease progression (61.9% for EVE?EXE vs
88.7% for PBO?EXE). Among the patients
who discontinued from treatment, the
proportion receiving new anticancer therapy
was numerically smaller in the EVE?EXE arm
compared with PBO?EXE (81% in the
EVE?EXE arm vs 91% in the PBO?EXE arm).
The most common post-study systemic
treatments in the EVE?EXE and PBO?EXE
arms included cytotoxic chemotherapy (42%
and 59% of patients, respectively), and
hormonal therapy (35% and 40% of patients,
respectively).
Efficacy
The addition of EVE to EXE significantly
prolonged median PFS versus EXE alone per
assessment by local investigators [7.8 vs
3.2 months, respectively; HR 0.45 (95%
confidence interval (CI) 0.38–0.54); log-rank
P\0.0001] (Fig. 1a). Analysis by central
assessment confirmed the PFS benefit
[11.0 months for EVE?EXE vs 4.1 months for
PBO?EXE; HR 0.38 (95% CI 0.31–0.48); log-
rank P\0.0001] (Fig. 1b). The effect of
EVE?EXE treatment (assessed by local
investigators) was consistent across patient
subgroups defined by patient characteristics
and prior therapy, with an estimated HR
ranging between 0.25 and 0.62 (Fig. 2a).
These analyses were concordant with similar
subgroup analyses from data based on central
review (Fig. 2b). In particular, EVE?EXE
treatment substantially extended PFS benefits
compared with PBO?EXE regardless of baseline
disease or prior therapy characteristics (e.g.,
only prior adjuvant therapy, prior
chemotherapy, and presence of visceral
metastases or bone lesions).
At the time of analysis, fewer deaths were
reported with EVE?EXE (25.4%) versus
PBO?EXE (32.2%; Table 2). A final analysis of
OS is planned after 398 events. Improvements
were also observed with EVE?EXE versus
PBO?EXE in overall response, objective
response rate, and CBR according to both local
and central assessments (Table 3).
Safety
The most commonly reported AEs (affecting
[25% of patients) in the EVE?EXE arm
included stomatitis, rash, fatigue, diarrhea,
nausea, decreased appetite, weight loss, and
cough, versus nausea and fatigue in the
PBO?EXE arm. The maximum grade of
toxicity was 1/2 for approximately half the
patients in the EVE?EXE arm. The most
common grade 3/4 AEs with EVE?EXE
included stomatitis, fatigue, dyspnea,
anemia, hyperglycemia, and gamma-
glutamyltransferase increase (Table 4). Gamma-
glutamyltransferase increase was the most
common grade 3/4 toxicity with PBO?EXE.
Despite the increased toxicity observed with
EVE?EXE versus PBO?EXE, health-related QOL
was not worse with EVE?EXE [19].
In the EVE?EXE arm, 66.8% of patients
required dose interruptions or reductions for
EVE and 23.9% of patients required dose
interruptions or reductions for EXE. In the
PBO?EXE arm, 11.8% of patients required
Adv Ther (2013) 30:870–884 875
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dose modifications for EXE. The most common
reasons for dose modification in both study
arms were AEs (62.4% for EVE in the EVE?EXE
arm vs 5.5% for EXE in the PBO?EXE arm).
Stomatitis (23.7%), pneumonitis (7.5%), and
thrombocytopenia (5.4%) were the most
common AEs leading to dose modifications in
the EVE?EXE arm (versus no single AE as a
predominant cause in the PBO?EXE arm).
Overall, the safety profile of EVE?EXE was
consistent with that reported at the interim
analysis [16].
Adverse events leading to discontinuation of
at least 1 study drug were reported in 26.3% of
patients in the EVE?EXE arm versus 5% of
patients in the PBO?EXE arm. Rates of AEs
leading to discontinuation that were suspected
to be related to at least 1 study drug were 21.4%
(EVE?EXE) versus 3.4% (PBO?EXE). The 2 most
common AEs leading to treatment
discontinuation in the EVE?EXE arm were
pneumonitis (5.6%) and stomatitis (2.7%). The
most common AEs leading to treatment
discontinuation in the PBO?EXE arm were
Fig. 1 Kaplan–Meier estimates of progression-free survival
of patients treated with everolimus plus exemestane versus
exemestane alone based on assessment by a local
investigator or b central review. CI confidence interval,
HR hazard ratio, EVE everolimus, EXE exemestane, PBO
placebo
876 Adv Ther (2013) 30:870–884
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laboratory abnormalities [increased gamma-
glutamyltransferase (1.7%) and increased
aspartate aminotransferase (1.3%)]. Higher
incidences of AEs, dose modifications, and
treatment discontinuation among EVE-treated
patients may, in part, be attributed to the longer
treatment duration in the EVE?EXE arm.
Details on dose modifications will be discussed
in another manuscript.
The incidence of death because of AEs was
1.4% among patients receiving EVE?EXE versus
0.4% among patients receiving PBO?EXE. In
the EVE?EXE arm, one death each was
attributed to pneumonia, sepsis,
staphylococcal sepsis, tumor hemorrhage,
ischemic stroke, suicide, and renal failure. In
the PBO?EXE arm, one death was attributed to
pneumonia.
Table 3 Summary of tumor response
Response Local assessment Central assessment
EVE1EXE
(n5 485)
PBO1EXE
(n5 239)
EVE1EXE
(n5 485)
PBO1EXE
(n5 239)
Best overall response (%)
Complete response (CR) 0.6 0 0 0
Partial response (PR) 12.0 1.7 12.6 2.1
Stable disease (SD) 71.3 59.0 73.4 62.8
Progressive disease 10.1 32.6 5.8 23.4
Unknown 6.0 6.7 8.2 11.7
ORR (CR or PR), % 12.6* 1.7 12.6 2.1
95% CI for ORR 9.8–15.9 0.5–4.2 9.8–15.9 0.7–4.8
CBR (CR?PR?SD C 24 weeks), % 51.3* 26.4 49.9 22.2
95% CI for CBR 46.8–55.9 20.9–32.4 45.4–54.4 17.1–28.0
CI confidence interval, CBR clinical benefit rate, EVE everolimus, EXE exemestane, ORR objective response rate, PBO
placebo
* Statistically significant difference, P\0.0001
Table 2 Between-arm differences in overall survival over time
PFS interim
(7-month follow-up)
PFS update
(12-month follow-up)
PFS final
(18-month follow-up)
Cutoff date Feb 11, 2011 Jul 8, 2011 Dec 15, 2011
OS events, n
EVE vs PBO, % of events
83
10.6 vs 13.0
137
17.3 vs 22.7
200
25.4 vs 32.2
D OS events, % of events 2.4 5.4 6.8
EVE everolimus, OS overall survival, PBO placebo, PFS progression-free survival, D change
Fig. 2 Subgroup analysis of progression-free survival by
a local investigator review and b central review. ECOG
Eastern Cooperative Oncology Group, EVE everolimus,
EXE exemestane, HR hazard ratio, NSAI nonsteroidal
aromatase inhibitor, PBO placebo, PFS progression-free
survival, PgR progesterone receptor
b
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Table 4 Most common adverse events (reported in C10% of patients)
AE (preferred term) EVE1EXE (n 5 482), % PBO1EXE (n 5 238), %
Grade Grade
All 1 2 3 4 All 1 2 3 4
Stomatitis 59 29 22 8 0 12 9 2 \1 0
Rash 39 29 9 1 0 7 5 2 0 0
Fatigue 37 18 14 4 \1 27 16 10 1 0
Diarrhea 34 26 6 2 \1 19 14 4 \1 0
Nausea 31 21 9 \1 \1 29 21 7 1 0
Decreased appetite 31 19 10 1 0 13 8 4 \1 0
Weight decreased 28 10 16 1 0 7 3 5 0 0
Cough 26 21 4 \1 0 12 8 3 0 0
Dysgeusia 22 18 4 0 0 6 6 0 0 0
Dyspnea 22 10 6 5 \1 11 8 2 \1 \1
Headache 23 17 6 \1 0 15 13 2 0 0
Arthralgia 21 15 5 \1 0 17 11 5 \1 0
Peripheral edema 21 14 6 1 0 6 5 \1 \1 0
Anemia 21 4 10 7 \1 5 2 2 \1 \1
Epistaxis 17 16 2 0 0 1 1 0 0 0
Vomiting 17 11 6 \1 \1 13 9 3 \1 0
Pyrexia 16 13 3 \1 0 7 5 \1 \1 0
Pneumonitis 16 7 6 3 0 0 0 0 0 0
Constipation 15 11 2 \1 0 13 8 5 \1 0
Back pain 15 10 5 \1 0 11 5 3 2 0
Pruritus 13 11 2 \1 0 5 3 2 0 0
Insomnia 14 10 4 \1 0 8 6 3 0 0
Asthenia 14 7 5 2 \1 4 3 \1 \1 0
AST increased 14 6 5 3 \1 5 2 2 1 0
Hyperglycemia 14 4 5 5 \1 2 \1 \1 \1 0
ALT increased 12 5 4 3 \1 5 \1 2 2 0
Dry mouth 11 10 1 0 0 7 7 \1 0 0
Alopecia 10 9 1 0 0 5 5 0 0 0
Nasopharyngitis 10 9 1 0 0 9 7 2 0 0
Pain in extremity 10 6 3 \1 0 12 5 5 2 0
Urinary tract infection 10 3 7 \1 0 2 \1 2 0 0
GGT increase 10 2 2 5 2 9 \1 \1 5 2
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, EVE everolimus, EXE exemestane, GGT
gamma-glutamyltransferase, PBO placebo
Adv Ther (2013) 30:870–884 879
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DISCUSSION
The current protocol-defined final analysis of
PFS from BOLERO-2 confirms the benefits of
EVE?EXE on PFS, the primary endpoint of the
trial, first reported at the interim analysis [16].
At 18-month median follow-up, EVE?EXE more
than doubled median PFS (as assessed by the
local investigator) versus PBO?EXE (an absolute
difference in median PFS [4 months) in
patients with HR?, HER2- advanced BC
recurring/progressing on/after initial NSAI
therapy. Moreover, subgroup analyses indicate
that EVE?EXE is an effective therapeutic option
in all patients, regardless of age, prior
chemotherapy in the advanced setting, visceral
disease, skeletal involvement, or setting of last
prior therapy [adjuvant/neoadjuvant (i.e., those
who recurred during or within 12 months of
completion of adjuvant treatment and received
study therapy as first-line treatment for
metastatic disease) or therapy for advanced/
metastatic disease]. No limitations of procedure
or protocol were observed during the conduct of
this study.
The central role of the mTOR pathway in BC
progression and integrating proliferative signals
provides a strong molecular rationale for
combining endocrine therapy with mTOR
inhibition. The results of the BOLERO-2 study
are remarkably similar to those of the
randomized phase 2 Tamoxifen Plus RAD-001
(TAMRAD) trial that compared EVE?TAM
versus TAM alone in a population of
metastatic BC patients who had progressed
after prior aromatase inhibitor (AI) therapy
[13]. In the TAMRAD study, EVE?TAM
prolonged median PFS to 8.6 months (versus
4.5 months with TAM; HR 0.54), and
demonstrated survival benefit (HR 0.45) [13].
Enhanced response in the neoadjuvant setting
has also been reported with the combination of
EVE with NSAI letrozole versus letrozole alone
[14].
The principal treatment goal for HR?
advanced BC is disease control. In this
context, the benefit of prolonging PFS is
clinically relevant provided patient QOL is
maintained. Analysis of patient-reported
outcomes from BOLERO-2 demonstrated that,
despite the higher incidence of AEs with
EVE?EXE versus EXE alone, QOL was
maintained [20]. These rates are slightly higher
than the rates reported at the interim analysis
[16], presumably because of increased drug
exposure with longer follow-up. This suggests
that the significantly improved clinical efficacy
outcomes achieved by adding EVE to EXE may
have outweighed the impact of toxicity [20].
Current guidelines recommend sequential
administration of another line of endocrine
therapy at relapse/progression after previous
endocrine therapy, whereas chemotherapy is
recommended for patients requiring rapid
symptom control or who have exhausted three
prior lines of endocrine treatment [2, 4].
Although endocrine therapy has a favorable
toxicity profile, second- or third-line endocrine-
directed approach has so far demonstrated
modest efficacy, with CBR ranging from 25%
to 35% [6, 8]. Randomized controlled
comparisons of experimental single [6, 7] or
combination endocrine agents [8, 10] showed
minimal to no improvement in median PFS or
time to progression versus EXE (3.7 months
post-NSAI) [6] or fulvestrant (from 4.4 months
post-NSAI to 6.5 months post-AI/antiestrogen)
[7]. In contrast, the BOLERO-2 study data
demonstrate that EVE?EXE significantly
improved median PFS by more than twofold
versus EXE alone.
Current guidelines also acknowledge that
cytotoxic chemotherapy regimens (whether
single agents or combinations) are generally
880 Adv Ther (2013) 30:870–884
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effective in controlling rapidly progressing
disease, but are associated with considerable
toxicity [8, 21]. Moreover, the clinical benefits
from sequential chemotherapy in patients
previously exposed to cytotoxic agents in the
adjuvant and/or metastatic setting may be
limited because of treatment resistance, as well
as the potential risk of cumulative toxicities
such as cardiac, gastrointestinal, hematologic,
and neurologic toxicities [21]. Given the
palliative intent of treatment in the second or
higher line of therapy and the toxicities
associated with chemotherapy, postponing the
initiation of cytotoxic therapy can be an
important consideration for patients and
physicians [22]. In this respect it is important
to note that all patient subsets [including those
with disease characteristics that might support
the use of chemotherapy (e.g., visceral
metastases and/or multiple metastatic sites)] in
the BOLERO-2 study experienced clinical
benefit similar to that of the overall
population treated with EVE?EXE.
The AE profile of EVE?EXE in this analysis
from BOLERO-2 after 18-month median follow-
up is consistent with the established safety
profile of EVE in other settings [23, 24].
Notably, these updated analyses show no
substantial risk of cumulative toxicities or new
safety signals despite a 60% increase in
cumulative treatment exposure in the
EVE?EXE arm. Adverse events of clinical
interest associated with EVE treatment
included stomatitis, rash, noninfectious
pneumonitis, infections, and metabolic
abnormalities, with the majority being grade
1/2. The majority of these events were
effectively resolved using protocol-defined
management strategies based on extensive
prior experience and resulting clinical
recommendations for the management of EVE-
related AEs in medical oncology (e.g., renal cell
carcinoma) [25–27]. Overall, vigilance and
proactive monitoring for signs and symptoms
of key AEs are key to facilitate prolonged
treatment with EVE [26].
CONCLUSION
The BOLERO-2 trial is the first phase 3 study to
demonstrate that dual blockade of the
endocrine and mTOR pathways is a feasible
and adequately tolerated strategy that provides
significant clinical benefit. The final analysis of
the primary endpoint from the BOLERO-2 study
demonstrates that EVE?EXE is well tolerated
and provides clinically meaningful PFS benefit
versus EXE alone in the overall population of
patients with HR? advanced BC progressing
during/after NSAI therapy, irrespective of age,
and among clinically relevant subsets of
patients including those receiving first-line
treatment for advanced disease, and patients
with visceral involvement. Overall, these data
support the use of combination therapy with
EVE?EXE to substantially improve PFS without
compromising QOL, thereby achieving an
important goal in the management of
advanced BC.
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